- Home
- LXEO vs NTHI Comparison
LXEO vs NTHI Comparison
Compare LXEO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- NTHI
- Stock Information
- Founded
- LXEO 2017
- NTHI 2008
- Country
- LXEO United States
- NTHI United States
- Employees
- LXEO N/A
- NTHI N/A
- Industry
- LXEO
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- NTHI Health Care
- Exchange
- LXEO Nasdaq
- NTHI Nasdaq
- Market Cap
- LXEO 93.9M
- NTHI 110.9M
- IPO Year
- LXEO 2023
- NTHI N/A
- Fundamental
- Price
- LXEO $4.49
- NTHI $4.75
- Analyst Decision
- LXEO Strong Buy
- NTHI
- Analyst Count
- LXEO 5
- NTHI 0
- Target Price
- LXEO $16.60
- NTHI N/A
- AVG Volume (30 Days)
- LXEO 520.2K
- NTHI 269.9K
- Earning Date
- LXEO 08-11-2025
- NTHI 01-01-0001
- Dividend Yield
- LXEO N/A
- NTHI N/A
- EPS Growth
- LXEO N/A
- NTHI N/A
- EPS
- LXEO N/A
- NTHI N/A
- Revenue
- LXEO N/A
- NTHI $79,990.00
- Revenue This Year
- LXEO N/A
- NTHI N/A
- Revenue Next Year
- LXEO N/A
- NTHI N/A
- P/E Ratio
- LXEO N/A
- NTHI N/A
- Revenue Growth
- LXEO N/A
- NTHI 13.52
- 52 Week Low
- LXEO $1.45
- NTHI $3.20
- 52 Week High
- LXEO $19.50
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- LXEO 63.76
- NTHI N/A
- Support Level
- LXEO $3.91
- NTHI N/A
- Resistance Level
- LXEO $4.85
- NTHI N/A
- Average True Range (ATR)
- LXEO 0.33
- NTHI 0.00
- MACD
- LXEO 0.02
- NTHI 0.00
- Stochastic Oscillator
- LXEO 78.69
- NTHI 0.00
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").